Publication & Citation Trends
Publications
160 total
Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers OA
Cited by 10
Semantic Scholar
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor. OA
Cited by 13
Semantic Scholar
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor OA
Cited by 105
Semantic Scholar
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. OA
Cited by 96
Semantic Scholar
Methylpyrrole inhibitors of BET bromodomains. OA
Cited by 17
Semantic Scholar
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. OA
Cited by 119
Semantic Scholar
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. OA
Cited by 56
Semantic Scholar
Abstract 3770: HEXIM1 as a pharmacodynamic marker for monitoring target engagement of ABBV-075
Cited by 0
Semantic Scholar
Research Topics
Protein Degradation and Inhibitors
(52)
Multiple Myeloma Research and Treatments
(48)
Cell death mechanisms and regulation
(34)
CAR-T cell therapy research
(23)
Ubiquitin and proteasome pathways
(19)
Affiliations
AbbVie (United States)
Abbott (United Kingdom)
University of Chicago
Abbott (United States)
May Institute